Market Place
Sourcing Support
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
03 Jun 2024 //
BUSINESSWIRE
CytRx Highlights ImmunityBio`s Use of Aldoxorubicin in Various Forms of Cancer
21 Dec 2021 //
BUSINESSWIRE
CytRx Highlights Use of Aldoxorubicin in Ph 2 Clinical Trials Yielding Positive
15 Jan 2021 //
BUSINESSWIRE
CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding
15 Jan 2021 //
NEWS
CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Ph2 Study
12 Oct 2020 //
BUSINESSWIRE
CytRx Corporation Highlights Significant +ve its Licensed Drug Aldoxorubicin
29 Jan 2020 //
PR NEWSWIRE
CytRx Corporation Highlights Significant Positive Events
19 Dec 2019 //
PR NEWSWIRE
FDA follows EMA in calling for a halt to new Lartruvo prescriptions
26 Jan 2019 //
ENDPTS
CytRx Corporation Highlights Aldoxorubicin`s Inclusion In New NantCell
14 Jan 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.